Navigation Links
Prasco Announces Agreement with Shire for Future Exclusive Distribution and Supply of Authorized Generic for PENTASA®
Date:2/22/2011

CINCINNATI, Feb. 22, 2011 /PRNewswire/ -- Prasco Laboratories announced today it has signed a distribution and supply agreement with Shire US Manufacturing, Inc. for mesalamine controlled-release capsules.  As part of the agreement, Prasco, LLC is prepared to market the authorized generic version of PENTASA® (mesalamine) Controlled-Release Capsules, at Shire's request, immediately upon any entrance into the United States market of an approved ANDA for any generic mesalamine product which is AB-rated to PENTASA®.  (At the present time, the FDA has not approved any ANDA for PENTASA®.)  The authorized generic will be marketed in the United States in 250 mg and 500 mg strengths under the Prasco label.

"We are excited to have established this new business relationship with Shire," stated Prasco Chief Executive Officer, E. Thomas Arington.  "Patients and pharmacists alike benefit when a company such as Shire commits to maintaining the supply of brand-identical medication through the Prasco Authorized Generic business model," Arington concluded.

PENTASA® is a registered trademark of Ferring A/S Corp.

About Prasco

Prasco is a privately-held pharmaceutical company located in Cincinnati, OH which specializes in Authorized Generics.  Prasco Authorized Generics provide brand pharmaceutical companies with a strategic lifecycle management solution. Prasco sells its product line through the major distribution channels, and operates from a cGMP compliant VAWD certified 160,000 sq. ft. office and distribution center including DEA-approved capabilities for Schedule II-V controlled drug products. For more information, visit www.prasco.com.  


'/>"/>
SOURCE Prasco Laboratories
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Prasco Enters into Agreements with sanofi-aventis U.S. to Provide Sales Support and Distribution Services for Authorized Generic Versions Under the Winthrop Label in U.S.
2. Prasco and Stiefel Sign Distribution and Supply Agreement for Clobetasol Propionate Foam
3. Prasco to Market Authorized Generic of ZEGERID®
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... , May 4, 2017  A recent study ... Ultraviolet-C light as a means of ... ability to reduce bioburden on anesthesia workstations. In ... on high-touch, complex medical equipment surfaces contaminated with ... "This study further validates the body ...
(Date:5/4/2017)... WAYNE, Pa. , May 4, 2017 /PRNewswire/ ... made from thermoplastics and other highly-engineered materials, is ... Microextrusion tubing has been developed in recent ... neurovascular interventional therapies and surgical applications. More expensive ... used to produce microextrusion tubing due to their ...
(Date:5/3/2017)... May 3, 2017  Getinge, a leading global ... quality enhancement and cost efficiency within healthcare and ... of contemporary practice demonstrating that intra-aortic balloon counterpulsation ... critically ill patients. The single-center, retrospective, observational study ... volume MEGA ® 50cc intra-aortic balloon (IAB) ...
Breaking Medicine Technology:
(Date:5/24/2017)... , ... May 24, 2017 , ... ... of ExtraHop to its solutions portfolio. ExtraHop delivers an analytics-first approach, layered with ... every IT system, from the datacenter to the cloud to the edge. Through ...
(Date:5/24/2017)... ... 24, 2017 , ... Fiberstar, Inc., http://www.FiberstarIngredients.com a ... beverage industry offers Citri-Fi®, a natural citrus fiber, to improve beverage ingredient declarations. ... a result, labels need to deliver simple, transparent and clear messaging. Listed food ...
(Date:5/23/2017)... ... , ... Allegheny Health Network and the Alexis Joy D’Achille ... Behavioral Health at West Penn Hospital , a unique facility that will offer ... depression. Construction of the Center is underway with a scheduled opening in the ...
(Date:5/23/2017)... ... 2017 , ... The National Council on Strength and Fitness ... organization’s Certified Strength Coach credential has earned accreditation from the National Commission for ... competency of qualified candidates for jobs in the Strength and Conditioning profession. The ...
(Date:5/23/2017)... New York (PRWEB) , ... May 23, 2017 ... ... NextGen LifeLabs, a leading equipment provider in the modern ART laboratory, to provide ... Institute in Ft. Lauderdale, Florida. , NextGen LifeLabs, a MedTech Group Purchasing ...
Breaking Medicine News(10 mins):